Overall, the AVAGAST trial underscored the role of VEGF signaling and its therapeutic potential in advanced gastric cancer and carcinomas of the esophagogastric junction, the latter representing 45 from 200 analyzed patients in Europe [22]. Here, VEGFA is linked to gastric cancer.